Risk of progressive multifocal leukoencephalopathy in patients with multiple sclerosis

Research output: Contribution to journalReview article

25 Citations (Scopus)

Abstract

Introduction: Multiple sclerosis (MS) is an autoimmune disorder that is characterized by inflammatory processes that lead to the destruction of myelin. Recently, several medications for MS that possess immune suppressing characteristics have been developed. As a consequence, cases of progressive multifocal leukoencephalopathy (PML) have been identified in MS patients. PML is potentially fatal, and specific strategies to minimize risk must be undertaken during therapy.Areas covered: A Medline search was performed to gather information about medications used to treat MS to assess the risk of PML with each. Specific risk factors for infection development are discussed and monitoring approaches are outlined.Expert opinion: Several medications have been associated with PML in MS patients, including natalizumab, fingolimod and dimethyl fumarate. Alemtuzumab and rituximab have been linked to cases of PML in other disease states. Consideration must be given to balancing efficacy with the potential for serious side effects, including PML. The severity of MS presentation may justify the use of a higher-risk medication at the outset. Increased diligence in obtaining MRIs and antibody status is essential as data demonstrate early identification of PML results in better outcomes. Lymphopenia and antibody index also appear to be reasonable factors to consider when choosing therapy.

Original languageEnglish
Pages (from-to)1737-1748
Number of pages12
JournalExpert Opinion on Drug Safety
Volume14
Issue number11
DOIs
StatePublished - Nov 2 2015

Fingerprint

Progressive Multifocal Leukoencephalopathy
Multiple Sclerosis
Lymphopenia
Antibodies
Expert Testimony
Myelin Sheath
Therapeutics
Infection

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)
  • Medicine(all)

Cite this

Risk of progressive multifocal leukoencephalopathy in patients with multiple sclerosis. / Faulkner, Michele A.

In: Expert Opinion on Drug Safety, Vol. 14, No. 11, 02.11.2015, p. 1737-1748.

Research output: Contribution to journalReview article

@article{1f9991f55aa648d5a65cc32cfb097146,
title = "Risk of progressive multifocal leukoencephalopathy in patients with multiple sclerosis",
abstract = "Introduction: Multiple sclerosis (MS) is an autoimmune disorder that is characterized by inflammatory processes that lead to the destruction of myelin. Recently, several medications for MS that possess immune suppressing characteristics have been developed. As a consequence, cases of progressive multifocal leukoencephalopathy (PML) have been identified in MS patients. PML is potentially fatal, and specific strategies to minimize risk must be undertaken during therapy.Areas covered: A Medline search was performed to gather information about medications used to treat MS to assess the risk of PML with each. Specific risk factors for infection development are discussed and monitoring approaches are outlined.Expert opinion: Several medications have been associated with PML in MS patients, including natalizumab, fingolimod and dimethyl fumarate. Alemtuzumab and rituximab have been linked to cases of PML in other disease states. Consideration must be given to balancing efficacy with the potential for serious side effects, including PML. The severity of MS presentation may justify the use of a higher-risk medication at the outset. Increased diligence in obtaining MRIs and antibody status is essential as data demonstrate early identification of PML results in better outcomes. Lymphopenia and antibody index also appear to be reasonable factors to consider when choosing therapy.",
author = "Faulkner, {Michele A.}",
year = "2015",
month = "11",
day = "2",
doi = "10.1517/14740338.2015.1093620",
language = "English",
volume = "14",
pages = "1737--1748",
journal = "Expert Opinion on Drug Safety",
issn = "1474-0338",
publisher = "Informa Healthcare",
number = "11",

}

TY - JOUR

T1 - Risk of progressive multifocal leukoencephalopathy in patients with multiple sclerosis

AU - Faulkner, Michele A.

PY - 2015/11/2

Y1 - 2015/11/2

N2 - Introduction: Multiple sclerosis (MS) is an autoimmune disorder that is characterized by inflammatory processes that lead to the destruction of myelin. Recently, several medications for MS that possess immune suppressing characteristics have been developed. As a consequence, cases of progressive multifocal leukoencephalopathy (PML) have been identified in MS patients. PML is potentially fatal, and specific strategies to minimize risk must be undertaken during therapy.Areas covered: A Medline search was performed to gather information about medications used to treat MS to assess the risk of PML with each. Specific risk factors for infection development are discussed and monitoring approaches are outlined.Expert opinion: Several medications have been associated with PML in MS patients, including natalizumab, fingolimod and dimethyl fumarate. Alemtuzumab and rituximab have been linked to cases of PML in other disease states. Consideration must be given to balancing efficacy with the potential for serious side effects, including PML. The severity of MS presentation may justify the use of a higher-risk medication at the outset. Increased diligence in obtaining MRIs and antibody status is essential as data demonstrate early identification of PML results in better outcomes. Lymphopenia and antibody index also appear to be reasonable factors to consider when choosing therapy.

AB - Introduction: Multiple sclerosis (MS) is an autoimmune disorder that is characterized by inflammatory processes that lead to the destruction of myelin. Recently, several medications for MS that possess immune suppressing characteristics have been developed. As a consequence, cases of progressive multifocal leukoencephalopathy (PML) have been identified in MS patients. PML is potentially fatal, and specific strategies to minimize risk must be undertaken during therapy.Areas covered: A Medline search was performed to gather information about medications used to treat MS to assess the risk of PML with each. Specific risk factors for infection development are discussed and monitoring approaches are outlined.Expert opinion: Several medications have been associated with PML in MS patients, including natalizumab, fingolimod and dimethyl fumarate. Alemtuzumab and rituximab have been linked to cases of PML in other disease states. Consideration must be given to balancing efficacy with the potential for serious side effects, including PML. The severity of MS presentation may justify the use of a higher-risk medication at the outset. Increased diligence in obtaining MRIs and antibody status is essential as data demonstrate early identification of PML results in better outcomes. Lymphopenia and antibody index also appear to be reasonable factors to consider when choosing therapy.

UR - http://www.scopus.com/inward/record.url?scp=84947491750&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84947491750&partnerID=8YFLogxK

U2 - 10.1517/14740338.2015.1093620

DO - 10.1517/14740338.2015.1093620

M3 - Review article

C2 - 26394704

AN - SCOPUS:84947491750

VL - 14

SP - 1737

EP - 1748

JO - Expert Opinion on Drug Safety

JF - Expert Opinion on Drug Safety

SN - 1474-0338

IS - 11

ER -